Literature DB >> 25415690

The use of proton therapy in the treatment of lung cancers.

Charles B Simone1, Ramesh Rengan.   

Abstract

Lung cancer is the leading cause of death from cancer in the United States and worldwide. Radiation therapy plays a prominent role in the treatment of patients with nonmetastatic disease. Radiation therapy alone can be curative for patients with stage I non-small cell lung cancer (NSCLC). Radiation therapy is also used as part of multimodality therapy to treat patients with locally advanced NSCLC. Current treatment delivery is often limited by radiation doses received by normal structures and treatment-related toxicities. Proton therapy for lung cancer can reduce the dose received by normal tissues, including the lungs, esophagus, and spinal cord, and may allow for reduced treatment toxicities. Proton therapy may also more safely allow for reirradiation and for radiation therapy to be combined with chemotherapy and surgery. This review discusses the rationales for and current uses of proton therapy to treat lung cancer, and it highlights key studies of proton therapy to treat early-stage and locally advanced NSCLC.

Entities:  

Mesh:

Year:  2014        PMID: 25415690     DOI: 10.1097/PPO.0000000000000080

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  22 in total

Review 1.  Cardiac toxicity of lung cancer radiotherapy.

Authors:  Radovan Vojtíšek
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-14

2.  Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies.

Authors:  Charles B Simone; Abigail T Berman; Salma K Jabbour
Journal:  Transl Lung Cancer Res       Date:  2017-04

3.  Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.

Authors:  Justin E Bekelman; Andrea Denicoff; Jeffrey Buchsbaum
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

4.  The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer.

Authors:  Xingzhe D Li; Charles B Simone
Journal:  Ann Transl Med       Date:  2019-12

5.  Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.

Authors:  Joe Y Chang; Wencheng Zhang; Ritsuko Komaki; Noah C Choi; Shen Chan; Daniel Gomez; Michael O'Reilly; Melenda Jeter; Michael Gillin; Xiaorong Zhu; Xiaodong Zhang; Radhe Mohan; Stephen Swisher; Stephen Hahn; James D Cox
Journal:  Radiother Oncol       Date:  2017-01-28       Impact factor: 6.280

Review 6.  Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.

Authors:  Charles B Simone; Stuart H Burri; John H Heinzerling
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 7.  Immunotherapy and radiation therapy for malignant pleural mesothelioma.

Authors:  Evan W Alley; Sharyn I Katz; Keith A Cengel; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 8.  Particle therapy in non-small cell lung cancer.

Authors:  Zhongxing Liao; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 9.  Proton therapy for thoracic reirradiation of non-small cell lung cancer.

Authors:  Hann-Hsiang Chao; Abigail T Berman
Journal:  Transl Lung Cancer Res       Date:  2018-04

10.  Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review.

Authors:  Vivek Verma; Steven H Lin; Charles B Simone; Minesh P Mehta
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.